Ata uhi

Small-Molecule Tyrosinase Inhibitors for Treatment of Hyperpigmentation

I tiakina i:
I whakaputaina i:Molecules vol. 30, no. 4 (2025), p. 788
Kaituhi matua: Ni, Xinhua
Ētahi atu kaituhi: Luo, Xinyu, Jiang, Xiaoying, Chen, Wenchao, Bai, Renren
I whakaputaina:
MDPI AG
Ngā marau:
Crystal structure
Physiology
Copper
Medical prognosis
Metastasis
Melanoma
Oxidation
Enzymes
Kinases
Radiation therapy
Biosynthesis
Skin cancer
Proteins
Molecules
Urunga tuihono:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
Whakarāpopotonga:Increasing attention is being focused on skin health currently, especially the excessive deposition of melanin in the skin. Tyrosinase, the rate-limiting enzyme in melanin biosynthesis, is a crucial enzyme in melanin synthesis. However, existing tyrosinase inhibitors pose some degree of toxicity to humans. Therefore, the development of more efficient and low-toxicity tyrosinase inhibitors is urgently needed. This review briefly depicts the melanin biosynthesis process and the crystal structure and catalytic mechanism of tyrosinase. The latest research progress regarding small-molecule tyrosinase inhibitors is also reviewed. Moreover, the structure–function relationships are analyzed and summarized. This is expected to provide new and more scientific insights to enable researchers to explore safer and more potent tyrosinase inhibitors.
ISSN:1420-3049
DOI:10.3390/molecules30040788
Puna:Health & Medical Collection